+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Seasonal Influenza: Competitive Landscape to 2026

  • PDF Icon


  • 49 Pages
  • November 2018
  • Region: Global
  • GlobalData
  • ID: 4703549
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Seasonal Influenza: Competitive Landscape to 2026


Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. The influenza A H1N1 and H3N2, and influenza B strains are those responsible for seasonal influenza infections. The symptoms of influenza are similar to those of the common cold, though they are usually more severe, have a sudden onset, last for one to two weeks, and are normally self-limiting without medical treatment. The very young, elderly, and patients with chronic illness such as diabetes, asthma, or cardiovascular disease are most at risk of complications due to influenza.

This report provides an assessment of the pipeline, clinical, and commercial landscape of seasonal influenza. Overall, The researchers expect new drug approvals to drive a shift in the treatment and prophylaxis of seasonal influenza over the next decade (2016-2026).


This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -
  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by product type

  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

  • Commercial Assessment: leading marketed products, current and future players

  • Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global seasonal influenza market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global seasonal influenza market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports
1.4 Upcoming Related Reports
2. Executive Summary
2.2 Key Findings
2.2 Key Events
3. Introduction
3.1 Report Scope
3.2 Disease Overview and Epidemiology
4. Pipeline Assessment
4.1 Pipeline Overview
4.2 Pipeline Breakdown by Region/Country
4.3 Pipeline Breakdown by Molecule Type and Target
4.4 Drug Review Designations
4.5 Products in Clinical Development
5. Clinical Trial Assessment
5.1 Clinical Trials Overview
5.2 Top Sponsors of Clinical Trials in Seasonal influenza
5.3 Trial Breakdown by Region
5.4 Therapy Area Perspective
5.5 Enrollment Analytics
6 Commercial Assessment
6.1 Leading Marketed Products
6.2 Current & Future Players
7. Competitive Landscape Analysis (2016-2026)
7.1 Events Classification Overview
7.2 US
7.3 5EU
7.4 Japan
8 Appendix
8.1 Sources
8.2 Methodology
8.3 Key Events Included in the Analysis
8.4 About the Authors
8.5 About the Publisher
8.6 Disclaimer

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie

  • Adimmune

  • Antigen Express

  • Beijing Minhai Biotechnology

  • Biken

  • BiondVax Pharmaceuticals

  • Codagenix

  • Daiichi Sankyo

  • Denka Seiken

  • Development Center for Biotechnology

  • F. Hoffmann-La Roche

  • Fluart Innovative Vaccines

  • FluGen

  • Folia Biotech

  • GC Pharma

  • GlaxoSmithKline

  • iBio

  • Institute of Virology Vaccines and Sera Torlak

  • Instituto Butantan

  • Japan Vaccine Co

  • Johnson & Johnson

  • Medicago

  • Mercia Pharma

  • Merck & Co

  • Mymetics

  • Nitto BioPharma

  • Novavax

  • Osaka City University

  • Path

  • Protein Sciences

  • Sanofi Pasteur

  • Scientific Research Institute for Biological Safety Problems

  • Seqirus

  • Shionogi

  • SK Bioscience

  • The Institute of Vaccines and Medical Biologicals

  • The National Institute of Allergy and Infectious Diseases

  • Vaxxas Pty

  • Vivaldi Biosciences